UBS Group AG grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) by 79.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 590,282 shares of the biopharmaceutical company’s stock after purchasing an additional 261,239 shares during the period. UBS Group AG owned about 0.57% of Catalyst Pharmaceuticals worth $10,979,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. FMR LLC lifted its stake in shares of Catalyst Pharmaceuticals by 24.2% in the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 822 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $31,000. Covestor Ltd grew its holdings in Catalyst Pharmaceuticals by 768.0% during the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,316 shares during the last quarter. Quantbot Technologies LP acquired a new position in Catalyst Pharmaceuticals during the first quarter valued at approximately $62,000. Finally, Point72 Hong Kong Ltd grew its holdings in Catalyst Pharmaceuticals by 63.0% during the first quarter. Point72 Hong Kong Ltd now owns 9,670 shares of the biopharmaceutical company’s stock valued at $80,000 after purchasing an additional 3,738 shares during the last quarter. 86.66% of the stock is owned by institutional investors and hedge funds.
Catalyst Pharmaceuticals Trading Up 2.3 %
NASDAQ CPRX opened at $12.45 on Tuesday. The stock’s 50 day moving average is $16.07 and its two-hundred day moving average is $16.52. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of 14.15 and a beta of 1.11. Catalyst Pharmaceuticals, Inc. has a 1-year low of $6.15 and a 1-year high of $22.11.
Insider Buying and Selling
In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 50,000 shares of the business’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $16.07, for a total value of $803,500.00. Following the transaction, the insider now owns 138,076 shares of the company’s stock, valued at $2,218,881.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Brian Elsbernd sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, March 20th. The shares were sold at an average price of $16.07, for a total value of $803,500.00. Following the completion of the sale, the insider now owns 138,076 shares of the company’s stock, valued at $2,218,881.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Patrick J. Mcenany sold 26,151 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $13.23, for a total transaction of $345,977.73. Following the completion of the sale, the chief executive officer now directly owns 3,945,436 shares of the company’s stock, valued at approximately $52,198,118.28. The disclosure for this sale can be found here. Insiders sold 246,151 shares of company stock worth $3,974,706 in the last quarter. 14.10% of the stock is owned by corporate insiders.
Analyst Ratings Changes
CPRX has been the subject of several research analyst reports. Cantor Fitzgerald boosted their price objective on Catalyst Pharmaceuticals from $22.00 to $25.00 in a research report on Friday, March 17th. StockNews.com cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, May 15th. Finally, Piper Sandler boosted their price objective on Catalyst Pharmaceuticals from $20.00 to $21.00 in a research report on Tuesday, February 7th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $21.50.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.
- Get a free copy of the StockNews.com research report on Catalyst Pharmaceuticals (CPRX)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.